What To Get Right Early In Subcutaneous Biologics Development

By Eva Keilhauer, Business Development Manager

Delivering biologic therapeutics via subcutaneous injection requires high-concentration formulations to fit necessary doses into low-volume delivery systems. However, increasing protein concentration exponentially elevates viscosity, drives colloidal instability, and accelerates aggregation risks.

Evaluating concentration feasibility early in development provides crucial biophysical insights without consuming extensive material. Integrating in silico modeling with targeted in vitro testing maps protonation curves, predicts protein-protein interactions, and pinpoints physical limits before critical process roadblocks occur. Systematic screening of pH and stabilizing excipients mitigates self-association, optimizing both syringeability and long-term product quality. Establishing early feasibility parameters prevents costly late-stage failures while maintaining manufacturability and patient adherence.

Explore the full asset to optimize high-concentration biopharmaceutical development and de-risk your pipeline strategy.